TY - JOUR
T1 - Fluorescein angiography and spectral-domain optical coherence tomography for monitoring Anti-VEGF therapy in myopic choroidal neovascularization
AU - Iacono, Pierluigi
AU - Battaglia Parodi, Maurizio
AU - Papayannis, Alexandros
AU - Kontadakis, Stylianos
AU - Da Pozzo, Stefano
AU - Cascavilla, Maria Lucia
AU - La Spina, Carlo
AU - Varano, Monica
AU - Bandello, Francesco
PY - 2014
Y1 - 2014
N2 - Aim: To evaluate the agreement between fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) in detecting myopic choroidal neovascularization (CNV) activity during bevacizumab treatment. Methods: Thirty-four patients with subfoveal myopic CNV were prospectively enrolled. FA and SD-OCT were performed at baseline and at all planned monthly visits. After the first injection, additional treatments were administered following detection of fluid on SD-OCT and/or leakage on FA. κ-Analysis was performed to examine the agreement between FA and SD-OCT. Results: At baseline, FA and SD-OCT agreed in 26/34 cases (κ = 0.23); sensitivity and specificity were 77.4 and 66.7%, respectively. Seven eyes presented leakage on FA with no fluid on SD-OCT, 1 case showed intraretinal fluid on SD-OCT and no leakage on FA. At the 1-month examination, specificity and κ-value improved, and 30/34 cases showed complete concordance. At the 3- and 4-month examinations, a discordance was noted in 6 cases. From the 5-month examination on, a correspondence was achieved in at least 30/34 cases and reached a perfect match in 11 sessions. Conclusions: Our study confirms the key role of FA in diagnosing myopic CNV. It seems possible there may be a role for SD-OCT in assisting FA to monitor the myopic CNV activity during anti-vascular endothelial growth factor antibody treatment.
AB - Aim: To evaluate the agreement between fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) in detecting myopic choroidal neovascularization (CNV) activity during bevacizumab treatment. Methods: Thirty-four patients with subfoveal myopic CNV were prospectively enrolled. FA and SD-OCT were performed at baseline and at all planned monthly visits. After the first injection, additional treatments were administered following detection of fluid on SD-OCT and/or leakage on FA. κ-Analysis was performed to examine the agreement between FA and SD-OCT. Results: At baseline, FA and SD-OCT agreed in 26/34 cases (κ = 0.23); sensitivity and specificity were 77.4 and 66.7%, respectively. Seven eyes presented leakage on FA with no fluid on SD-OCT, 1 case showed intraretinal fluid on SD-OCT and no leakage on FA. At the 1-month examination, specificity and κ-value improved, and 30/34 cases showed complete concordance. At the 3- and 4-month examinations, a discordance was noted in 6 cases. From the 5-month examination on, a correspondence was achieved in at least 30/34 cases and reached a perfect match in 11 sessions. Conclusions: Our study confirms the key role of FA in diagnosing myopic CNV. It seems possible there may be a role for SD-OCT in assisting FA to monitor the myopic CNV activity during anti-vascular endothelial growth factor antibody treatment.
KW - Anti-vascular endothelial growth factor antibody
KW - Intravitreal bevacizumab
KW - Pathological myopia
KW - Spectral-domain optical coherence tomography
KW - Subfoveal myopic choroidal neovascularization
UR - http://www.scopus.com/inward/record.url?scp=84901141142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901141142&partnerID=8YFLogxK
U2 - 10.1159/000358331
DO - 10.1159/000358331
M3 - Article
C2 - 24861045
AN - SCOPUS:84901141142
VL - 52
SP - 25
EP - 31
JO - Ophthalmic Research
JF - Ophthalmic Research
SN - 0030-3747
IS - 1
ER -